BIO-Europe is under way in Cologne, and obesity remains one of the most talked-about areas on the partnering floor. While much of the attention is still on GLP-1 drugs, Pila Pharma is pitching a different approach: a TRPV1-targeting pill for obesity, with the first participants in its new study dosed in October. BioStock caught up with CEO Gustav Gram on the first day of the conference to hear about the mood on the floor and what the company hopes to take home.
Watch the interview at biostock.se :
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se